We expected that a HER2 assay performed on LCM ovarian cancer cells purified from all surrounding cells would greatly increase the reliability of the HER2 analysis compared with, e.g., the FISH analysis, where there is a risk of misinterpreting stromal and inflammatory cells as cancer cells. The gene discussed is ERBB2; the disease is ovarian carcinoma.